- Recently reported positive six-month immunogenicity data for IVX-121 against RSV; first clinical evidence of potential differentiation on durability with company’s VLP platform - - Phase 1 study of IVX-A12 (a bivalent of IVX-121 for RSV and IVX-241 for hMPV) progressing and on track for topline